ADC Therapeutics S.A. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NYSE |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
ADC Therapeutics S.A. (ADCT) holds an ST Score of 48.7 out of 100 (C+), with its strongest factor being Growth (A-) and its weakest Momentum (D). Analysts rate ADCT Hold across 12 ratings with a $3.50 average price target (+2.1% vs the current $1.12).
- Strongest
- GrowthA-
- Weakest
- MomentumD
All factor grades
- GrowthA-
- ForecastB+
- ProfitabilityB
- ValuationB-
- Financial StrengthC+
- MomentumD
- Piotroski1/9
Contact
ADCT stock: frequently asked questions
What is ADCT's ST Score?
ADC Therapeutics S.A. (ADCT) has an ST Score of 48.7 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ADCT a buy, sell, or hold?
Wall Street's consensus rating on ADCT is Hold based on 12 analyst ratings. Our own ST Score grades it C+ (48.7/100). This is data, not investment advice — always do your own research.
What is ADCT's valuation grade?
ADC Therapeutics S.A. (ADCT) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ADCT's growth grade?
ADC Therapeutics S.A. (ADCT) earns a growth grade of A-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ADCT's profitability grade?
ADC Therapeutics S.A. (ADCT) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ADCT's financial strength grade?
ADC Therapeutics S.A. (ADCT) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ADCT?
The average analyst price target for ADC Therapeutics S.A. (ADCT) is $3.50 from 12 analysts, which is +2.1% versus the recent price of $1.12.
What is ADCT's Piotroski score?
ADC Therapeutics S.A. (ADCT) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.